Insider Trading History of Favorito Tamara A

The following table details the insider trading activities (stock purchases, stock sales, and stock option exercises) of Favorito Tamara A since 2015. This trader's CIK number is 1288232. At the time of last reporting, Favorito Tamara A was the Director of Zevra Therapeutics, Inc.. (stock ticker symbol ZVRA). Also see all insider trading activities at Zevra Therapeutics, Inc..

Note that in the past FAVORITO TAMARA A also reported insider trading activities as an insider of the following companies:

Yearly summary of insider trading at Zevra Therapeutics, Inc. (ZVRA) by Favorito Tamara A

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2025 ZVRA 3,175 $24,717 0 $0 0 $0
2023 ZVRA 519 $2,502 0 $0 0 $0
2022 ZVRA 200 $974 0 $0 0 $0

Yearly summary of insider trading at Viridian Therapeutics, Inc.\de (SGNL) by Favorito Tamara A

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2016 SGNL 0 $0 0 $0 169,000 $0
2015 SGNL 0 $0 0 $0 23,000 $0


Insider trading activities at 2 companies by Favorito Tamara A:

1. Zevra Therapeutics, Inc. (ZVRA)

2. Viridian Therapeutics, Inc.\de (SGNL)

Table 1. Insider trading of Zevra Therapeutics, Inc. (ZVRA) by Favorito Tamara A

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2025-09-12 ZVRA Buy 3,175 7.79 24,717
2023-03-17 ZVRA Buy 519 4.82 2,502
2022-05-20 KMPH Buy 200 4.87 974

Table 2. Insider trading of Viridian Therapeutics, Inc.\de (SGNL) by Favorito Tamara A

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2016-10-31 SGNL Option Ex 146,000 .00 0
2016-08-08 SGNL Option Ex 23,000 .00 0
2015-08-04 SGNL Option Ex 23,000 .00 0

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Favorito Tamara A (Director of Zevra Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.



©2023, insider-monitor.com. All rights reserved.